
- ONCOLOGY Vol 21 No 14
- Volume 21
- Issue 14
Medicare Increases Hospital Reimbursement Rates for Prostate Cancer Cryoablation
federal Centers for Medicare and Medicaid Services (CMS) have increased their hospital outpatient and ambulatory surgical center reimbursement rates for cryoablation treatments for prostate cancer
The federal Centers for Medicare and Medicaid Services (CMS) have increased their hospital outpatient and ambulatory surgical center reimbursement rates for cryoablation treatments for prostate cancer. The new rates, which were proposed in August and will go into effect in 2008, were confirmed on November 1, 2007.
The new 2008 CMS rates for prostate cryoablation performed in an outpatient hospital setting for patients who do not stay overnight, under APC code 674, were raised from $6,685.05 to $7,816.10, a 16.9% increase. The cryoablation rates for ambulatory surgical centers, known as ASC code 55873, were raised from $1,339.00 to $6,219.63, an increase of 364%.
Endocare Chairman, CEO, and President Craig T. Davenport said: "We believe these changes underscore the fact that cryoablation is becoming a more accepted treatment with physicians and continues to receive positive reimbursement from CMS. We are very pleased that hospitals and ambulatory surgical centers will receive these increased payments and know these changes will assist Medicare members to obtain cryoablation treatment in these outpatient settings."
Cryoablation is a minimally invasive treatment that uses the Endocare CryoCare Surgical System to precisely target, freeze, and destroy cancerous tissue.
Articles in this issue
almost 18 years ago
Cetuximab Improves Survival in Advanced Colorectal Canceralmost 18 years ago
Hyperthermia/Chemotherapy Combination Doubles Survival in Sarcoma Patientsalmost 18 years ago
Treating Bladder Cancer: Neoadjuvant vs Adjuvant Therapyalmost 18 years ago
Managing CLL: A New Level of Sophisticationalmost 18 years ago
Key Issues in Treating Frail Elderly Breast Cancer Patientsalmost 18 years ago
Introductionalmost 18 years ago
Clinical Malignant Hematologyalmost 18 years ago
Erlotinib in Pancreatic Cancer: A Major Breakthrough?Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.